FDA黑框警告!氟喹诺酮类药品需慎用!

2016-07-28 佚名 医学界药学频道

2016年7月26日,FDA批准更新氟喹诺酮类药物(包括口服制剂和注射液)的药品标签。氟喹诺酮类药物全身用药时致残性和潜在的永久性严重不良反应可同时发生,这些不良反应累及肌腱、肌肉、关节、神经和中枢神经系统,因此FDA不但修订了黑框警告,特别强调用药的安全性问题,此外FDA还增加了新的警告,且同步更新了药品标签中用药指南等其他内容。此次FDA更新了氟喹诺酮类药品标签中的黑框警告,并增加了新的警告,

2016年7月26日,FDA批准更新氟喹诺酮类药物(包括口服制剂和注射液)的药品标签。


氟喹诺酮类药物全身用药时致残性和潜在的永久性严重不良反应可同时发生,这些不良反应累及肌腱、肌肉、关节、神经和中枢神经系统,因此FDA不但修订了黑框警告,特别强调用药的安全性问题,此外FDA还增加了新的警告,且同步更新了药品标签中用药指南等其他内容。


此次FDA更新了氟喹诺酮类药品标签中的黑框警告,并增加了新的警告,还修订了患者用药指南等内容。具体内容如下:

黑框警告

原有的黑框警告:氟喹诺酮类药物可能引起肌腱炎、肌腱断裂和重症肌无力病情恶化的警告标签。

新增黑框警告:氟喹诺酮类药物可能致残及并发多种永久性严重不良反应。

警告及注意事项:

原有警告:氟喹诺酮类药物可能引起肌腱炎、肌腱断裂和重症肌无力病情恶化、外周神经病变风险及中枢神经系统不良反应,还包括一些心脏、皮肤及过敏反应等严重不良反应。

新增(进一步加强警告):氟喹诺酮类药物全身用药时致残性和潜在的永久性严重不良反应可同时发生,这些不良反应包括肌腱炎、肌腱断裂、中枢神经系统相关反应、重症肌无力恶化、外周神经系统病变、QT间期延长、尖端扭转型室速及光毒性。这些不良反应可发生在用药后几小时内至几周内,且几种不良反应可能会同时发生。

适应证和用法:

增加了新的限制使用说明:急性细菌性鼻窦炎(ABS)、慢性支气管炎的急性细菌感染性恶化(ABECB)、单纯性尿路感染患者使用氟喹诺酮类抗菌药品治疗引发相关严重不良反应的风险通常大于效益,因此针对上述疾病,氟喹诺酮类药品应该仅用于那些没有其他方案可供选择的患者。


此外氟喹诺酮类药物可用于治疗炭疽病、瘟疫、细菌性肺炎等严重细菌感染患者,获益大于风险。


用药指南:

患者用药指南中新增要求:在给患者开具喹诺酮类处方时,应让每位患者都了解具体的药物安全性问题。

氟喹诺酮类药物不良反应


氟喹诺酮类全身性使用的严重不良反应:


肌肉、骨骼及外周神经系统

中枢神经系统

其它器官及系统

肌腱炎

焦虑

重症肌无力的恶化

肌腱断裂

抑郁

皮疹

麻木、刺痛、手臂及腿部刺痛感“针样刺痛”

幻觉

晒伤(光毒性)

肌无力

自杀倾向

心脏搏动异常、快速强烈

肌痛

困惑

严重腹泻

关节痛




氟喹诺酮类药物的常见不良反应:恶心、腹泻、头痛、头晕、晕眩或入睡困难。


目前FDA批准的全身性使用的氟喹诺酮类药物


莫西沙星

环丙沙星

环丙沙星缓释剂

吉米沙星

左氧氟沙星

氧氟沙星


FDA建议


如果患者服用喹诺酮类药物,一旦出现任何严重不良反应及相关症状,如肌腱、关节、肌肉疼痛,针样刺痛或刺痛感,混乱和幻觉,应及时告诉医务人员。医务人员应立即对出现严重不良反应的患者停药,并选择非氟喹诺酮类抗菌药进行后续治疗。FDA同时希望患者和医务人员积极上报相关药物不良反应。FDA表示将会继续跟进喹诺酮类药物的安全问题,并及时更新最新消息。


附:FDA曾经发布过的氟喹诺酮类药物安全信息通报

2008年7月,FDA要求氟喹诺酮类抗生素生产者增加关于药物可能引起肌腱炎和肌腱断裂事件的黑框警告。对于老年人、肾、心、肺脏移植者或者同时应用激素治疗的人来说,应用氟喹诺酮更容易发生肌腱炎或肌腱断裂。

2013年8月,FDA要求更新全身应用的喹诺酮类药物的使用说明书及相关用药指导,以便更好地提醒这类药物可能导致严重外周神经病变。外周神经病变的症状包括上下肢的疼痛、烧灼感、麻木、物力或者任何深浅感觉的改变。

2016年5月,FDA发布了一项药物安全性通知,严格限制氟喹诺酮类抗菌药用于鼻窦炎、支气管炎和非复杂性泌尿道感染患者,警告其可能致残甚至并发多种永久性不良反应。


FDA针对氟喹诺酮发出安全警告,限制其使用


参考资料:http://www.fda.gov/Drugs/DrugSafety/ucm511530.htm

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1928428, encodeId=a70b192842812, content=<a href='/topic/show?id=3cf54018620' target=_blank style='color:#2F92EE;'>#喹诺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40186, encryptionId=3cf54018620, topicName=喹诺酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Sat Dec 03 02:08:00 CST 2016, time=2016-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95162, encodeId=70769516212, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9ce350198, createdName=el891227, createdTime=Sat Jul 30 19:11:00 CST 2016, time=2016-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523090, encodeId=72651523090d3, content=<a href='/topic/show?id=fe8663915a3' target=_blank style='color:#2F92EE;'>#氟喹诺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63915, encryptionId=fe8663915a3, topicName=氟喹诺酮)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff0911497072, createdName=doctorzheng, createdTime=Sat Jul 30 13:08:00 CST 2016, time=2016-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95110, encodeId=73e3951105b, content=引起重视,多观察,及时与病患沟通,按需调整药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a68d1929696, createdName=1e0c81e1m19(暂无匿称), createdTime=Sat Jul 30 05:52:00 CST 2016, time=2016-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95061, encodeId=71a99506139, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Fri Jul 29 17:55:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95062, encodeId=35b195062f2, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Fri Jul 29 17:55:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95013, encodeId=6ba69501350, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=79111662974, createdName=xiangbaodada, createdTime=Fri Jul 29 07:02:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95005, encodeId=655295005a9, content=临床上遇到过这样的先例!, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230812/e93037ddfed9425fb0316dc3e904f2f4/870c0a4383ef42ef803173fea0339be3.jpg, createdBy=27ba1551982, createdName=huangzh898, createdTime=Fri Jul 29 05:54:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95004, encodeId=5ed19500454, content=!!!!!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuIjZYTAgkEia1SFuoeAByVaQC8uXegibpJEV2Q7SqhpDINJicNiaU5pYicYmy5WsI8l5hDribViac2A1BQ9/0, createdBy=c36f1724608, createdName=hfuym10906, createdTime=Fri Jul 29 05:28:00 CST 2016, time=2016-07-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1928428, encodeId=a70b192842812, content=<a href='/topic/show?id=3cf54018620' target=_blank style='color:#2F92EE;'>#喹诺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40186, encryptionId=3cf54018620, topicName=喹诺酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Sat Dec 03 02:08:00 CST 2016, time=2016-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95162, encodeId=70769516212, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9ce350198, createdName=el891227, createdTime=Sat Jul 30 19:11:00 CST 2016, time=2016-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523090, encodeId=72651523090d3, content=<a href='/topic/show?id=fe8663915a3' target=_blank style='color:#2F92EE;'>#氟喹诺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63915, encryptionId=fe8663915a3, topicName=氟喹诺酮)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff0911497072, createdName=doctorzheng, createdTime=Sat Jul 30 13:08:00 CST 2016, time=2016-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95110, encodeId=73e3951105b, content=引起重视,多观察,及时与病患沟通,按需调整药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a68d1929696, createdName=1e0c81e1m19(暂无匿称), createdTime=Sat Jul 30 05:52:00 CST 2016, time=2016-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95061, encodeId=71a99506139, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Fri Jul 29 17:55:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95062, encodeId=35b195062f2, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Fri Jul 29 17:55:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95013, encodeId=6ba69501350, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=79111662974, createdName=xiangbaodada, createdTime=Fri Jul 29 07:02:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95005, encodeId=655295005a9, content=临床上遇到过这样的先例!, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230812/e93037ddfed9425fb0316dc3e904f2f4/870c0a4383ef42ef803173fea0339be3.jpg, createdBy=27ba1551982, createdName=huangzh898, createdTime=Fri Jul 29 05:54:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95004, encodeId=5ed19500454, content=!!!!!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuIjZYTAgkEia1SFuoeAByVaQC8uXegibpJEV2Q7SqhpDINJicNiaU5pYicYmy5WsI8l5hDribViac2A1BQ9/0, createdBy=c36f1724608, createdName=hfuym10906, createdTime=Fri Jul 29 05:28:00 CST 2016, time=2016-07-29, status=1, ipAttribution=)]
    2016-07-30 el891227

    有用

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1928428, encodeId=a70b192842812, content=<a href='/topic/show?id=3cf54018620' target=_blank style='color:#2F92EE;'>#喹诺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40186, encryptionId=3cf54018620, topicName=喹诺酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Sat Dec 03 02:08:00 CST 2016, time=2016-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95162, encodeId=70769516212, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9ce350198, createdName=el891227, createdTime=Sat Jul 30 19:11:00 CST 2016, time=2016-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523090, encodeId=72651523090d3, content=<a href='/topic/show?id=fe8663915a3' target=_blank style='color:#2F92EE;'>#氟喹诺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63915, encryptionId=fe8663915a3, topicName=氟喹诺酮)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff0911497072, createdName=doctorzheng, createdTime=Sat Jul 30 13:08:00 CST 2016, time=2016-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95110, encodeId=73e3951105b, content=引起重视,多观察,及时与病患沟通,按需调整药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a68d1929696, createdName=1e0c81e1m19(暂无匿称), createdTime=Sat Jul 30 05:52:00 CST 2016, time=2016-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95061, encodeId=71a99506139, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Fri Jul 29 17:55:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95062, encodeId=35b195062f2, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Fri Jul 29 17:55:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95013, encodeId=6ba69501350, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=79111662974, createdName=xiangbaodada, createdTime=Fri Jul 29 07:02:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95005, encodeId=655295005a9, content=临床上遇到过这样的先例!, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230812/e93037ddfed9425fb0316dc3e904f2f4/870c0a4383ef42ef803173fea0339be3.jpg, createdBy=27ba1551982, createdName=huangzh898, createdTime=Fri Jul 29 05:54:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95004, encodeId=5ed19500454, content=!!!!!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuIjZYTAgkEia1SFuoeAByVaQC8uXegibpJEV2Q7SqhpDINJicNiaU5pYicYmy5WsI8l5hDribViac2A1BQ9/0, createdBy=c36f1724608, createdName=hfuym10906, createdTime=Fri Jul 29 05:28:00 CST 2016, time=2016-07-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1928428, encodeId=a70b192842812, content=<a href='/topic/show?id=3cf54018620' target=_blank style='color:#2F92EE;'>#喹诺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40186, encryptionId=3cf54018620, topicName=喹诺酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Sat Dec 03 02:08:00 CST 2016, time=2016-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95162, encodeId=70769516212, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9ce350198, createdName=el891227, createdTime=Sat Jul 30 19:11:00 CST 2016, time=2016-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523090, encodeId=72651523090d3, content=<a href='/topic/show?id=fe8663915a3' target=_blank style='color:#2F92EE;'>#氟喹诺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63915, encryptionId=fe8663915a3, topicName=氟喹诺酮)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff0911497072, createdName=doctorzheng, createdTime=Sat Jul 30 13:08:00 CST 2016, time=2016-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95110, encodeId=73e3951105b, content=引起重视,多观察,及时与病患沟通,按需调整药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a68d1929696, createdName=1e0c81e1m19(暂无匿称), createdTime=Sat Jul 30 05:52:00 CST 2016, time=2016-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95061, encodeId=71a99506139, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Fri Jul 29 17:55:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95062, encodeId=35b195062f2, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Fri Jul 29 17:55:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95013, encodeId=6ba69501350, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=79111662974, createdName=xiangbaodada, createdTime=Fri Jul 29 07:02:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95005, encodeId=655295005a9, content=临床上遇到过这样的先例!, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230812/e93037ddfed9425fb0316dc3e904f2f4/870c0a4383ef42ef803173fea0339be3.jpg, createdBy=27ba1551982, createdName=huangzh898, createdTime=Fri Jul 29 05:54:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95004, encodeId=5ed19500454, content=!!!!!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuIjZYTAgkEia1SFuoeAByVaQC8uXegibpJEV2Q7SqhpDINJicNiaU5pYicYmy5WsI8l5hDribViac2A1BQ9/0, createdBy=c36f1724608, createdName=hfuym10906, createdTime=Fri Jul 29 05:28:00 CST 2016, time=2016-07-29, status=1, ipAttribution=)]
    2016-07-30 1e0c81e1m19(暂无匿称)

    引起重视,多观察,及时与病患沟通,按需调整药物

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1928428, encodeId=a70b192842812, content=<a href='/topic/show?id=3cf54018620' target=_blank style='color:#2F92EE;'>#喹诺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40186, encryptionId=3cf54018620, topicName=喹诺酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Sat Dec 03 02:08:00 CST 2016, time=2016-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95162, encodeId=70769516212, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9ce350198, createdName=el891227, createdTime=Sat Jul 30 19:11:00 CST 2016, time=2016-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523090, encodeId=72651523090d3, content=<a href='/topic/show?id=fe8663915a3' target=_blank style='color:#2F92EE;'>#氟喹诺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63915, encryptionId=fe8663915a3, topicName=氟喹诺酮)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff0911497072, createdName=doctorzheng, createdTime=Sat Jul 30 13:08:00 CST 2016, time=2016-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95110, encodeId=73e3951105b, content=引起重视,多观察,及时与病患沟通,按需调整药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a68d1929696, createdName=1e0c81e1m19(暂无匿称), createdTime=Sat Jul 30 05:52:00 CST 2016, time=2016-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95061, encodeId=71a99506139, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Fri Jul 29 17:55:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95062, encodeId=35b195062f2, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Fri Jul 29 17:55:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95013, encodeId=6ba69501350, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=79111662974, createdName=xiangbaodada, createdTime=Fri Jul 29 07:02:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95005, encodeId=655295005a9, content=临床上遇到过这样的先例!, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230812/e93037ddfed9425fb0316dc3e904f2f4/870c0a4383ef42ef803173fea0339be3.jpg, createdBy=27ba1551982, createdName=huangzh898, createdTime=Fri Jul 29 05:54:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95004, encodeId=5ed19500454, content=!!!!!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuIjZYTAgkEia1SFuoeAByVaQC8uXegibpJEV2Q7SqhpDINJicNiaU5pYicYmy5WsI8l5hDribViac2A1BQ9/0, createdBy=c36f1724608, createdName=hfuym10906, createdTime=Fri Jul 29 05:28:00 CST 2016, time=2016-07-29, status=1, ipAttribution=)]
    2016-07-29 doctorJiangchao

    继续学习

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1928428, encodeId=a70b192842812, content=<a href='/topic/show?id=3cf54018620' target=_blank style='color:#2F92EE;'>#喹诺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40186, encryptionId=3cf54018620, topicName=喹诺酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Sat Dec 03 02:08:00 CST 2016, time=2016-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95162, encodeId=70769516212, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9ce350198, createdName=el891227, createdTime=Sat Jul 30 19:11:00 CST 2016, time=2016-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523090, encodeId=72651523090d3, content=<a href='/topic/show?id=fe8663915a3' target=_blank style='color:#2F92EE;'>#氟喹诺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63915, encryptionId=fe8663915a3, topicName=氟喹诺酮)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff0911497072, createdName=doctorzheng, createdTime=Sat Jul 30 13:08:00 CST 2016, time=2016-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95110, encodeId=73e3951105b, content=引起重视,多观察,及时与病患沟通,按需调整药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a68d1929696, createdName=1e0c81e1m19(暂无匿称), createdTime=Sat Jul 30 05:52:00 CST 2016, time=2016-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95061, encodeId=71a99506139, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Fri Jul 29 17:55:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95062, encodeId=35b195062f2, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Fri Jul 29 17:55:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95013, encodeId=6ba69501350, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=79111662974, createdName=xiangbaodada, createdTime=Fri Jul 29 07:02:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95005, encodeId=655295005a9, content=临床上遇到过这样的先例!, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230812/e93037ddfed9425fb0316dc3e904f2f4/870c0a4383ef42ef803173fea0339be3.jpg, createdBy=27ba1551982, createdName=huangzh898, createdTime=Fri Jul 29 05:54:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95004, encodeId=5ed19500454, content=!!!!!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuIjZYTAgkEia1SFuoeAByVaQC8uXegibpJEV2Q7SqhpDINJicNiaU5pYicYmy5WsI8l5hDribViac2A1BQ9/0, createdBy=c36f1724608, createdName=hfuym10906, createdTime=Fri Jul 29 05:28:00 CST 2016, time=2016-07-29, status=1, ipAttribution=)]
    2016-07-29 doctorJiangchao

    继续关注

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1928428, encodeId=a70b192842812, content=<a href='/topic/show?id=3cf54018620' target=_blank style='color:#2F92EE;'>#喹诺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40186, encryptionId=3cf54018620, topicName=喹诺酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Sat Dec 03 02:08:00 CST 2016, time=2016-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95162, encodeId=70769516212, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9ce350198, createdName=el891227, createdTime=Sat Jul 30 19:11:00 CST 2016, time=2016-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523090, encodeId=72651523090d3, content=<a href='/topic/show?id=fe8663915a3' target=_blank style='color:#2F92EE;'>#氟喹诺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63915, encryptionId=fe8663915a3, topicName=氟喹诺酮)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff0911497072, createdName=doctorzheng, createdTime=Sat Jul 30 13:08:00 CST 2016, time=2016-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95110, encodeId=73e3951105b, content=引起重视,多观察,及时与病患沟通,按需调整药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a68d1929696, createdName=1e0c81e1m19(暂无匿称), createdTime=Sat Jul 30 05:52:00 CST 2016, time=2016-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95061, encodeId=71a99506139, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Fri Jul 29 17:55:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95062, encodeId=35b195062f2, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Fri Jul 29 17:55:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95013, encodeId=6ba69501350, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=79111662974, createdName=xiangbaodada, createdTime=Fri Jul 29 07:02:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95005, encodeId=655295005a9, content=临床上遇到过这样的先例!, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230812/e93037ddfed9425fb0316dc3e904f2f4/870c0a4383ef42ef803173fea0339be3.jpg, createdBy=27ba1551982, createdName=huangzh898, createdTime=Fri Jul 29 05:54:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95004, encodeId=5ed19500454, content=!!!!!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuIjZYTAgkEia1SFuoeAByVaQC8uXegibpJEV2Q7SqhpDINJicNiaU5pYicYmy5WsI8l5hDribViac2A1BQ9/0, createdBy=c36f1724608, createdName=hfuym10906, createdTime=Fri Jul 29 05:28:00 CST 2016, time=2016-07-29, status=1, ipAttribution=)]
    2016-07-29 xiangbaodada

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1928428, encodeId=a70b192842812, content=<a href='/topic/show?id=3cf54018620' target=_blank style='color:#2F92EE;'>#喹诺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40186, encryptionId=3cf54018620, topicName=喹诺酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Sat Dec 03 02:08:00 CST 2016, time=2016-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95162, encodeId=70769516212, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9ce350198, createdName=el891227, createdTime=Sat Jul 30 19:11:00 CST 2016, time=2016-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523090, encodeId=72651523090d3, content=<a href='/topic/show?id=fe8663915a3' target=_blank style='color:#2F92EE;'>#氟喹诺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63915, encryptionId=fe8663915a3, topicName=氟喹诺酮)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff0911497072, createdName=doctorzheng, createdTime=Sat Jul 30 13:08:00 CST 2016, time=2016-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95110, encodeId=73e3951105b, content=引起重视,多观察,及时与病患沟通,按需调整药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a68d1929696, createdName=1e0c81e1m19(暂无匿称), createdTime=Sat Jul 30 05:52:00 CST 2016, time=2016-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95061, encodeId=71a99506139, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Fri Jul 29 17:55:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95062, encodeId=35b195062f2, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Fri Jul 29 17:55:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95013, encodeId=6ba69501350, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=79111662974, createdName=xiangbaodada, createdTime=Fri Jul 29 07:02:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95005, encodeId=655295005a9, content=临床上遇到过这样的先例!, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230812/e93037ddfed9425fb0316dc3e904f2f4/870c0a4383ef42ef803173fea0339be3.jpg, createdBy=27ba1551982, createdName=huangzh898, createdTime=Fri Jul 29 05:54:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95004, encodeId=5ed19500454, content=!!!!!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuIjZYTAgkEia1SFuoeAByVaQC8uXegibpJEV2Q7SqhpDINJicNiaU5pYicYmy5WsI8l5hDribViac2A1BQ9/0, createdBy=c36f1724608, createdName=hfuym10906, createdTime=Fri Jul 29 05:28:00 CST 2016, time=2016-07-29, status=1, ipAttribution=)]
    2016-07-29 huangzh898

    临床上遇到过这样的先例!

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1928428, encodeId=a70b192842812, content=<a href='/topic/show?id=3cf54018620' target=_blank style='color:#2F92EE;'>#喹诺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40186, encryptionId=3cf54018620, topicName=喹诺酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Sat Dec 03 02:08:00 CST 2016, time=2016-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95162, encodeId=70769516212, content=有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9ce350198, createdName=el891227, createdTime=Sat Jul 30 19:11:00 CST 2016, time=2016-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523090, encodeId=72651523090d3, content=<a href='/topic/show?id=fe8663915a3' target=_blank style='color:#2F92EE;'>#氟喹诺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63915, encryptionId=fe8663915a3, topicName=氟喹诺酮)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff0911497072, createdName=doctorzheng, createdTime=Sat Jul 30 13:08:00 CST 2016, time=2016-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95110, encodeId=73e3951105b, content=引起重视,多观察,及时与病患沟通,按需调整药物, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a68d1929696, createdName=1e0c81e1m19(暂无匿称), createdTime=Sat Jul 30 05:52:00 CST 2016, time=2016-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95061, encodeId=71a99506139, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Fri Jul 29 17:55:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95062, encodeId=35b195062f2, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Fri Jul 29 17:55:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95013, encodeId=6ba69501350, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=79111662974, createdName=xiangbaodada, createdTime=Fri Jul 29 07:02:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95005, encodeId=655295005a9, content=临床上遇到过这样的先例!, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230812/e93037ddfed9425fb0316dc3e904f2f4/870c0a4383ef42ef803173fea0339be3.jpg, createdBy=27ba1551982, createdName=huangzh898, createdTime=Fri Jul 29 05:54:00 CST 2016, time=2016-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=95004, encodeId=5ed19500454, content=!!!!!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuIjZYTAgkEia1SFuoeAByVaQC8uXegibpJEV2Q7SqhpDINJicNiaU5pYicYmy5WsI8l5hDribViac2A1BQ9/0, createdBy=c36f1724608, createdName=hfuym10906, createdTime=Fri Jul 29 05:28:00 CST 2016, time=2016-07-29, status=1, ipAttribution=)]
    2016-07-29 hfuym10906

    !!!!!!!

    0

相关资讯

Clin Infect Dis :氟喹诺酮或增严重心律失常风险

  加拿大和意大利联合研究表明,氟喹诺酮应用与严重心律失常风险升高相关,但各药物间存在一定差异。论文发表于《临床感染病》[Clin Infect Dis 2012, 55 (11): 1457]杂志。   研究者在魁北克健康数据库中选取1990年1月1日至2005年12月31日间因呼吸系统疾病接受治疗患者,随访至2007年3月31日,据

FDA针对氟喹诺酮发出安全警告,限制其使用

FDA发出安全警报:治疗鼻窦炎、支气管炎、单纯性尿路感染时,只有在没有其他可供选择方案的情况下,才能使用氟喹诺酮类药物,因为该药物相关的不良事件风险超过了药物带来的益处。FDA在安全审查中发现氟喹诺酮类药物(片剂、胶囊和注射剂)可能存在肌腱、肌肉、关节、神经和中枢神经系统的致残性和潜在的永久性不良反应。FDA要求所有氟喹诺酮类药物标签和用药指南更新指定的信息。如果患者出现诸如肌腱疼痛、关节疼痛、肌

FDA再发警告,限制喹诺酮的使用,细数其罪状!

在医院实习那会儿,氟喹诺酮类药物用的那可是叫一个多啊,各种沙星天天都在用(诺氟沙星、培氟沙星、依诺沙星、氧氟沙星、环丙沙星......)。偶然间看到前几天FDA发布的对氟喹诺酮的安全警告,限制其使用,于是问了几个医生小盆友,哎哟喂,现在医院氟喹诺酮类药物用的也不少啊,于是心里咯噔了一下,对近几年著名机构或研究发布的关于氟喹诺酮类药物严重不良反应的警告进行了总结,希望大家能牢

NAT GENET :艰难梭菌全球流行原因被识别

       最新研究显示,由两种不同的菌株,而不是只有一种,导致了2002~2006年艰难梭菌全球流行。这两种菌株对一线抗生素氟喹诺酮产生了耐药性。对治疗的抵抗和该细菌产生的高度感染性孢子使该细菌在全球迅速传播。        艰难梭菌感染结肠的内层,其产生的毒素可导致严重炎症和腹泻。在发达国家,艰难梭菌感染是

盘点:氟喹诺酮的功与过

喹诺酮类药物(4-quinolones),又称吡酮酸类或吡啶酮酸类,是一类较新的合成抗菌药。这类药物抗菌谱广、抗菌力强、口服吸收好,组织浓度高,与其他抗菌药物无交叉耐药性,不良反应相对较少等特点,已经成为治疗细菌感染性疾病的主要药物。 最早应用的如萘啶酸(nalidixic acid)和吡哌酸(pipemidic acid),仅用于泌尿道和肠道感染,因疗效差、耐药性发展迅速,应用日趋

加拿大警告氟喹诺酮的视网膜脱离风险

加拿大卫生部不久前发布信息,警示口服氟喹诺酮类药物与视网膜脱离的风险。 氟喹诺酮类药物是广谱抗菌药物,适用于治疗敏感菌株导致的感染。加拿大上市的口服氟喹诺酮类药物有环丙沙星、左氧氟沙星、莫西沙星、诺氟沙星和氧氟沙星,在任何口服氟喹诺酮类药物的说明书中均没有视网膜脱离风险的描述。氟喹诺酮类药物是广谱抗菌药物,适用于治疗敏感菌株导致的感染。加拿大上市的口服氟喹诺酮类药物有环丙沙星、左氧氟沙星、莫西沙